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Medication safety forms part of patient safety,
but what about drug safety?
Erkki Palva
Professor
National Agency for Medicines (NAM)
Editorial
In January this year, the Ministry of Social Affairs
and Health published its Finnish Patient Safety Strat-
egy for 2009–2013. The aim of this strategy is to en-
sure safe, effective treatment. At the operational lev-
el this is realised through adherence to principles
and methods that guarantee safe treatment and pro-
tect patients from harm.
Key elements in promoting patient safety include
training, processes and structures, good practice,
and learning from mistakes. These elements apply to
the activities of organisations and to the people
working in them, and they allow hazardous events
occurring as a result of this work to be prevented.
Within the drug treatment process, medication
safety forms part of patient safety, and is concerned
with processes ranging from the prescription and ad-
ministration of the drug to associated follow-up
measures. Processes need to be developed with the
help of benchmarks. A paper on this subject looks at
benchmarks and the auditing of medication safety as
development tools for use in hospital environments.
Drug safety is often to some extent understood to
be the opposite of medication safety – in other
words it is seen to be restricted to product safety
and to evaluating substances’ properties. But the
specification for a drug includes not just its percepti-
ble pharmacological effect, but also its therapeutic
indication. When we talk about safe therapeutic in-
dications, we are already looking at process guide-
lines for drug treatment. A very common observa-
tion in studies examining the frequency of undesir-
able effects of drugs is that over half of the undesir-
able effects leading to hospitalisation could have
been prevented. In these cases, improving the
process allows the level of safety to be increased.
A medicinal product that has been granted mar-
keting authorisation is much more than a mere
chemical compound in a package. The approved
product’s marketing authorisation also covers an ex-
tensive information pack in the form of a summary
of product characteristics that specifies e.g. dosage,
therapeutic indications, contraindications, necessary
precautions and follow-up procedures, and some-
times also describes how to monitor the drug re-
sponse and the emergence of any undesirable effects.
A prerequisite for the use of many new drugs is of-
ten familiarity with a training package focusing on
minimising risks. Similar information necessary for
the user of the drug will be included in the package
leaflet.
Instead of being seen as mutually exclusive, drug
and medication safety should be seen as a seamless
continuum that serves to ensure that drugs produce
the best possible effect, and to protect patients from
any adverse events. Simply including safety guide-
lines in the summary of product characteristics is
not enough – guidelines also need to be correctly fol-
lowed in practice. Reporting safety problems that
can occur in drug treatment practice is an important
tool for improving product information as guidelines
for use of the drug.
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Regulation of drug marketing and drug information
Kristiina Pellas
Senior Pharmaceutical Inspector
National Agency for Medicines (NAM)
Erkki Palva
Professor 
National Agency for Medicines (NAM)
Nearly 50 reports were processed
by NAM’s drug marketing regula-
tion section in 2008. Where mar-
keting of prescription drugs to the
public was possibly involved, im-
proved efficiency in regulation was
targeted at drug company opera-
tions. Year by year the distribution
of health information about dis-
eases and their symptoms including
treatment alternatives has increased
in the media. 
Background information about
drug marketing regulation at
NAM
NAM regulates the appropriateness
of drug marketing in Finland,
mainly according to the standards
stipulated in the Medicines Act and
Decree. Relevant EU Directives
(2001/83/EC and 2004/27/EC)
have been included in the Medi-
cines Act and Decree. Even more
detailed specifications about drug
marketing are contained in Sections
91 to 93 of the Medicines Act con-
tain stipulations about drug mar-
keting. Sections 25 and 25 a to i of
the Medicines Decree.
For example, regulation of drug
marketing at NAM comprises in
practice follow-up of marketing
and the review of possible defaults
and their rectification as well as
advice relating to marketing issues.
The most important part of the
regulation concerns the review that
takes place following reports of
suspected misconduct relating to
marketing submitted by medical
professionals, the authorities, drug
companies or private individuals.
As far as regulation is concerned,
most of these reports or complaints
have been successfully resolved by
NAM through requesting a report
from or sending a caution to the
relevant party. Only one case in
2008 advanced to the stage of mar-
keting prohibition being imposed.
One third of the requests for a re-
port involved the marketing of a
prescription drug to the public, one
third concerned inappropriate mar-
keting of a prescription drug and
one third that of an over-the-
counter drug.
Regarding prescription drugs,
the requests for a report were often
concerned with inappropriate fig-
ures or choices of the wording or
insufficient information about the
safe and correct use of the product
in the relevant advertisement. Sus-
pected marketing of prescription
drugs to the public concerned
health campaigns which contained
indirect or direct sales promotion
for a particular product.
At the beginning of 2009, a sys-
tematic review was made of the in-
formation given by drug companies
on their websites about drugs or
therapy groupings. This will be-
come a relevant topic within the
next few years because of a new
proposition for a directive at pre-
sent being discussed at EU level re-
garding the drug information that
is being offered to patients.
Informative content of the drug
companies’ websites
Health information targeted at the
public in general which does not
even indirectly aim to promote the
sales of any specific medicinal
product falls in the category of
freedom of speech and is allowed.
In NAM’s view the borderline be-
tween information and marketing
should not be obscured. The truth
is nevertheless that companies do
offer information about the groups
of therapy and diseases for which
they have an appropriate drug in
their ranges of products. Improve-
ment of the level of information
the patients receive can for exam-
ple generate both an improved out-
come of treatment and unnecessary
medications by creating impres-
sions of a need of medication for
diseases associated with the high
standard of living.
At present, the informative con-
tent of the websites examined falls
as a rule into the category of infor-
mation compliant with freedom of
speech. According to this review, as
to their extent and scientific na-
ture, the informative contents of
drug company websites vary signif-
icantly.
Of the websites examined
(n=131) 44% (57) were in the
Finnish language; 90% of these
had the package leaflet and/or data
about the summary of product in-
formation either published in
Finnish or gave a link to the proper
site. The links were to the website
of NAM or to the database of
www.lääkeinfo.fi. It is important
that the information approved by
the authorities about the drugs
should be easily available to pa-
tients on the Internet.
Health information in the
Finnish language about prescrip-
tion drugs or information oriented
towards the disease or symptoms
by therapy groups was published
by 23 (40%) drug companies. The
websites of these 23 drug compa-
Summary
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nies were examined further in
greater detail. There were 140 of
them in total. The websites includ-
ed a mention of 163 groups of
therapy. The majority of the web-
sites involved issues relating to
cancer and blood diseases followed
in frequency by sites involving is-
sues relating to psychotic and neu-
rological diseases.
In accordance with various
groups of therapy, basic informa-
tion on the drug company websites
is published about diseases, occa-
sionally including additional infor-
mation about cell level changes in
the various diseases. The websites
very often discuss the symptoms
and frequency of a disease and the
risk factors for it. Some sites also
include information about the vari-
ous alternative methods for detect-
ing the disease, the tests necessary
and the interpretation of laborato-
ry results. More extensive sites dis-
cuss information about the preva-
lence of the disease, various treat-
ment alternatives and advice on
change of lifestyle. On the more
advanced websites patients are
prompted to turn to medical ex-
perts with their queries about the
company’s prescription drugs.
The proposition for a directive
on information about prescription
drugs given to patients is at pre-
sent being discussed by the Euro-
pean Commission and Parliament.
NAM also submitted a statement
on the issue at the beginning of the
year. NAM does not support the
idea of giving drug companies nov-
el opportunities for distribution of
information, except for informa-
tion about summaries of product
characteristics and package
leaflets. In NAM’s opinion, the
borderline between information
and marketing should not be ob-
scured. NAM does not support the
new directive in all its parts be-
cause, among other considerations,
it would increase the regulatory
workload of the authorities. The
increase in drug information re-
ferred to in the directive may in
fact increase the number of doc-
tor’s appointments made by the
population, the use of drugs and
drug costs. The future will show
what type of information drug
companies may distribute to pa-
tients in the future.
According to the latest legislation
from the National Agency for
Medicines, hospital pharmacies
must have an internal monitoring
program to ensure medication
safety in their associated hospital
units. To enable a monitoring pro-
gramme of this kind to be devel-
oped, a study was carried out at
Satakunta Central Hospital as a
part of the regional “Safe Pharma-
cotherapy” programme. The main
objective of this research was to
enable medication safety audits to
be performed on the basis of a val-
idated self-assessment tool, and to
implement this activity as a hospi-
tal pharmacy-directed practice. A
medication safety audit is an inter-
nal review which assesses the ap-
propriateness of the pharmacother-
apy plan on the basis of medica-
tion safety criteria. The audit tool
was based on the original self-as-
sessment tool (241 items) created
by ISMP (Institute of Safe Medica-
tion Practices), which has been
used extensively in the United
States. The original tool was
adapted to take account of Finnish
healthcare practices and the modi-
fied version (121 items) was tested
at the pilot ward. The self-assess-
ment responses were discussed by
the audit pharmacist and senior
nurse during the audit visit. The
area in which the highest number
of guidelines were found to be ei-
ther fully or partially in place was
“pharmaceutical services” (89 %),
which includes the ordering, stor-
age, preparation and return of
drugs. The section in which the
lowest number of guidelines were
observed to be fully/partially in
place was “the pharmacotherapy
process” (22%), which involves
the transmission of the prescrip-
tion for and prescription, labelling,
distribution and administration of
drugs, patient information and
counselling, and assessing the ef-
fectiveness of pharmacotherapy. 
The medication safety audit is a
new tool for integrating pharma-
cists into nursing care in hospital
wards, in compliance with national
safe pharmacotherapy guidelines.
Medication safety audits could also
improve the scope of pharmaceuti-
cal services in primary healthcare
wards, especially those that do not
have their own pharmacy units.
However, in order for this type of
pharmacy-initiated medication
safety programme to be imple-
mented regularly, healthcare pro-
fessionals will need to be prepared
to take on new roles.
Ercan Celikkaylar, M.Sc. (Pharm.), 
Satakunta Central Hospital, 
Hospital Pharmacy 
Marja Airaksinen, Ph.D. professor, 
University of Helsinki, Faculty of Pharmacy,
Division of Social Pharmacy
Leena Astala, M.Sc. (Pharm.), 
Luvia Pharmacy
Pharmacy-initiated internal monitoring program
as a tool for improving medication safety – 
medication safety audit at Satakunta Central Hospital
Telithromycin and visual disturbances
Our patient cases
Case no. 1. The first patient is a
34-year-old female member of an
airline company’s flying person-
nel. She is a healthy women. She
had previously experienced aller-
gic reaction after the administra-
tion of phenoxy methyl peni-
cillin. Following a flight she
sought treatment for ear symp-
toms. Auroscopy and anterior
rhinoscopy revealed perceptible
swelling and poor mobility of the
tympanic membranes, together
with postnasal irritation and pro-
fuse drip. The patient was pre-
scribed a 5-day course of
telithromycin 800 mg daily. She
was also given a spray of be-
clomethasone dipropionate.
Within 30 minutes of the first
dose of telithromycin she experi-
enced a visual disturbance. She
was unable to focus her sight
properly and various items ap-
peared distorted. Since she took
the drug in the evening, she was
unable to evaluate the duration
of the symptom. In the morning,
however, her eye sight had re-
turned to normal. She continued
taking the medication and visual
symptoms no longer appeared.
At an appointment four days
thereafter the patient’s vision was
normal for both reading and at 5
metres’ distance. Eye movements
were normal, and using finger
perimetry the visual fields were
found to be normal, as were the
fundi of the eyes. Distortion of
images did not occur in the pa-
tient’s vision. Romberg’s test was
steady, blood pressure while seat-
ed was 124/84 mm Hg and the
pulse was regular 72/min.
Case no. 2. A 33-year-old male
patient is presented as a further
case. He had previously been in
good basic health, but phenoxy
methyl penicillin had provoked
an allergic reaction. He had had
a very sore throat and a profuse
postnasal drip for about  a week.
He was found to have coating of
the pharyngeal mucosa and
swollen palatal tonsils. His tym-
panic membranes were normal
and his lungs were found to be
normal on auscultation. He was
prescribed telithromycin 800 mg
daily for seven days. Following
the first dose of this drug the pa-
tient could not detect anything
unusual, but 2 to 3 hours after
the second dose he felt stiff and
almost as if inebriated. He also
described objects in his surround-
ing vision as having become dis-
torted. He reported these symp-
toms by telephone. He subse-
quently stopped using the med-
ication and was asked to consult
if symptoms persisted.
Background
Telithromycin (Ketek) is a ke-
tolide antibiotic which has been
in use in Finland since 2002.
Ketek has been granted cen-
tralised marketing authorisation
in the EU, and the safety of this
medicinal substance is mainly
regulated by the European Medi-
cines Agency, EMEA. In 2007
EMEA stipulated restrictions on
the use of telithromycin after an
extensive evaluation of safety of
the drug (1). EMEA focused on
the therapeutic indications and
certain undesirable effects of
telithromycin in particular. Its
significant undesirable effects in-
clude transient visual distur-
bances. An additional warning
on telithromycin associated visu-
al disturbances was included in
the Summary of Product Infor-
mation (SPC), stating that “be-
cause of the possibility of visual
disturbances patients should min-
imise activities such as driving a
vehicle, using heavy machinery
or performing similar hazardous
tasks”. Prescribers were also re-
minded that patients should be
informed about the possibility of
this undesirable effect emerging
even following the initial dose.
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Radhakrishnan Rajaratnam
Senior Medical Officer
National Agency for Medicines (NAM)
Alpo Vuorio
M.D., MAvMED
Medical Center Mehiläinen Airport
Own observation of
an adverse reaction
TABU 2. 2009 45
In English
Table 1. ADR reports concerning telithromycin and visual disturbances (Adverse drug reaction register of NAM, DLP 31.3.2009).
Age and
sex
Latent time MedDRA terms for the
adverse reactions
Description of the adverse reaction Recovery Discontinuation of
medication 
36 y. 
female 
6 days Blurred vision, 
Arrhythmia,
Hypoaesthesia
Blurred vision half an hour after intake of tablet;
lasted for a couple of hours.
Recovered without
special treatment 
Discontinued
37 y. 
female 
Less than one
day 
Blurred vision,
Malaise
Symptoms started one hour after intake of the
first tablet at 1 p.m. and continued until late at
night.
Recovered
44 y. 
male 
Less than one
day
Blurred vision Blurred vision after intake of the first tablet; the
vision was not restored to normal for the rest of
the day.
Unknown
40 y. 
male 
9 days Blurred vision, 
Nuchal rigidity
Visual acuity became impaired. Had not recovered by
the day of reporting
23 y. 
female 
2 days Blurred vision,
Dizziness
About 30 to 45 minutes following initial intake of
the drug developed dizziness and blurred vision
on long sight.
Recovered after 
restling
Discontinued
32 y.
female
One day Visual disturbance, 
Eye pain
Prolonged visual disturbance and pain in the eye. Unknown
35 y. 
male 
Less than one
day
Abnormal 
accommodation 
Impaired accommodation one hour after intake
of drug, unable to read or to see for a short 
distance, and unable to even see his doctor 
clearly. 
Unknown
38 y. 
female
Less than one
day
Visual disturbance,
Dizziness
Visual disturbance, dizziness. Unknown Discontinued
34 y.
female
One day Abnormal vision 30 minutes after intake of drug difficulties seeing
accurately at a short distance, also long distance
e.g. TV text. Distortion of image also 
occurred.
Recovered Discontinued after 
4 days
44  y. 
female
Less than one
day
Abnormal vision Difficulties in seeing at a short distance. Recove-
red before intake of subsequent tablets, and
symptom-free after the course of treatment.
Recovered A 5-day course of
treatment
26  y.
female
Less than one
day
Abnormal vision, 
Dizziness
Visual disturbance and dizzines lasting for a
couple of hours after each intake of tablet.
Recovered Discontinued
42 y. 
female
Abnormal accommoda-
tion, Diplopia 
About 1.5 hours after intake of drug difficulties
supervened in accommodation, visual field ap-
peared blurred and diplopia developed.
Recovered the following
day after discontinua-
tion of medication
Discontinued
50 y. 
female
Less than one
day
Abnormal vision The patient was unable to see clearly either at a
short or a long distance.
Recovered
25 y. 
female
Less than one
day
Oculogyric crisis The eyes were paralysed, shifting of vision beca-
me difficult.
Recovered on the 
same day
30 y.
female 
Less than one
day
Abnormal vision, Eye
pain, Speech disorder
45 minutes after intake of drug, visual distur-
bances developed, the eyes were sore, and speech
was blurred.
Recovered during fol-
low-up in hospital
53 y.
female
Less than one
day
Diplopia, Headache,
Dizziness, Insomnia,
Diarrhoea
Headache developed about 2 hours after intake
of drug. Other symptoms on the second day
including double vision.
Had not recovered by
the day of reporting
Discontinued
17 y.
male 
One day Blurred vision Blurred vision lasting for a couple of hours develo-
ped about 2 hours after intake of drug, unable to
do computer work and the TV appeared unclear. 
Had not recovered by
the day of reporting
Discontinued after 
4 days
27 y. 
female
Less than one
day
Abnormal vision, 
Dizziness, Nausea
Dizziness developed about half an hour after in-
tak of drug, together with difficulties on locating
the visual field for about 1.5 hours.
Recovered Discontinued
15 y. 
female
Less than one
day
Blurred vision Blurred vision on the day of the use of the drug. Recovered A 5-day course of
treatment
25 y. 
female
Diplopia, Headache,
Blurred vision, Dizziness,
Feeling strange
Tinnitus and double vision developed during the se-
cond 5-day course of treatment about 48 hours af-
ter intake of drug. The symptoms lasted  for 3 weeks.
Had not recovered by
the day of reporting
Visual disturbances 
associated with the use of
telithromycin
A total of 52 reports of suspected
adverse reactions related to the
use of telithromycin have been
reported to the NAM’s ADR reg-
ister until the cut-off date of
March 31, 2009. Of  the 52 re-
ports, 20 cases were related to
various visual disturbances
(Table 1). Three quarters of the
reports on visual disturbance
concerned young adults (20 to
40 years old). The majority,
85%, were of female patients.
Ten patients (50%) did not ex-
hibit any other symptoms besides
visual disturbances. The onset of
symptoms usually occurred 30
minutes to 2 hours after the in-
take of the drug and lasted for
over 2 hours. Over half of the
patients (12) recovered, and
symptoms in four patients con-
tinued during the time of report-
ing. The course of treatment with
telithromycin was discontinued
in seven patients due to adverse
reactions. Four patients contin-
ued with their course of treat-
ment despite the adverse reac-
tion.
Discussion
The approved  therapeutic indi-
cations of telithromycin in adults
include outpatient treatment of
pneumonia, exacerbation of
chronic bronchitis and acute si-
nusitis if the infection is known
to be betalactam and/or
macrolide resistant. 
Visual disturbances related to
telithromycin should be kept in
mind in the clinical practice.
Telithromycin has been reported
to have caused visual distur-
bances including blurred vision,
difficulties of visual acuity and
double vision. In their degree of
severity they have generally var-
ied from mild to moderate, but
severe cases have also occurred.
According to a recent analysis
of data from an Italian adverse
reaction register, adverse reac-
tions associated with the eye dis-
orders were 2.2% of the reports
(n=1 017) (3). In this register, the
majority of the eye disorder re-
ports concerning tablet form
were on telithromycin. In another
recent Italian analysis of macro-
lide antibiotic induced eye reac-
tions (n=622 cases) revealed that
telithromycin had caused 47% of
the cases (4). A further analysis
showed that the most common
adverse reactions were blurred vi-
sion (43%), unspecified visual
disturbance (19%), impaired vi-
sual acuity (14%) and double vi-
sion (10%). The majority of
these reactions emerged after the
first or second dose and were re-
versible. In only a few of these
cases was no immediate recovery
seen. Even though telithromycin
is not known to have caused per-
manent visual disturbance, re-
peating the course of telithro-
mycin treatment is warned
against if it has caused visual dis-
turbance (5). Repeated use could
in theory result in optic neuropa-
thy (5).
About 40% of the adverse re-
action cases reported to NAM
where telithromycin was a sus-
pected medication are associated
with visual disturbance. The risk
of visual disturbance associated
with the use of telithromycin ap-
pears to be transient. It is not
known whether this is dose de-
pendent. According to FDA, visu-
al disturbance occurred in 0.4%
of the subjects (40/1 003) in
phase I studies during high dose
therapy and in 0.7% of the pa-
tients (14/2 045) in phase III
studies (2). Visual disturbances
were mostly reported in females
under the age of 40 years. Ac-
cording to analysis by EMEA, the
frequency of visual disturbance is
estimated at 1% (1). Telithro-
mycin-associated  visual distur-
bances were studied in two trials;
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the mechanism may be a short-
acting effect of telithromycin on
the ciliary body causing a delay
in the relaxation of the ciliary
muscle and visual acuity being
consequently impaired (1).
This review has focused on
telithromycin-associated  visual
disturbances. With regard to oth-
er potential adverse reactions it
should be borne in mind that the
most common ADRs are gas-
trointestinal disorders and head-
ache (1, 6). Use of telithromycin
may also have resulted in severe
adverse reactions such as exacer-
bation of myasthenia gravis,
transient loss of consciousness,
hepatic failure or even irre-
versible liver damage. Before the
treatment with telithromycin
risks should be carefully weighed
against the benefits. In certain
difficult situations, taking a big-
ger risk can be considered in the
treatment of a severe infection
(7). The safety profile of teli-
thromycin is being continuously
monitored. 
Summary
The visual disturbances are occa-
sionally associated with the use
of telithromycin, and the risk is
greater than with the use of other
antibiotics. It is recommended
that the risk of this adverse reac-
tion which appears to be higher
in females under the age of 40
years be consistently kept in
mind in the clinical practice. The
advice already mentioned in the
SPC should be followed, i.e.
“while using telithromycin pa-
tients should minimise activities
such as driving a vehicle, using
heavy machinery or performing
similar hazardous tasks”. Taking
telithromycin before bedtime can
decrease the potential complica-
tions of visual disturbances.
Literature
See page 19.
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The medicinal products to be
tested are selected e.g. on the ba-
sis of product defect reports, risk
evaluation, and random sam-
pling. The strategic preferences of
NAM are taken into considera-
tion in setting up sampling and
testing plans. The medicinal
products are usually ordered
from wholesales. Inspectors sam-
ple both active pharmaceutical
ingredients and medicinal prod-
ucts when they inspect pharma-
ceutical industries and pharma-
cies. Samples from other Euro-
pean countries are obtained in
projects where the NAM-labora-
tory has the responsibility to test
medicines within the frame of the
joint EU/EEA- testing schemes.
NAM also participates in the
work of the European Pharma-
copoeia Commission and its
Groups of Experts. The duty of
the Groups of Experts is to elab-
orate and update the European
Pharmacopoeia monographs. The
Finnish OMCL has been repre-
sented in the European Pharma-
copoeia Commission since 1975
and in the Groups of Experts
since 1978.
Testing the wide variety of
medicines
Testing the wide variety of medi-
cines places high demands on the
personnel, facilities, and equip-
ment. Many methods are needed
ranging from chemical methods
like mass spectrometry and capil-
lary electrophoresis to sterility
testing and determination of en-
dotoxins. 
In addition to the common
synthetic medicines, novel biolog-
ical medicinal products become
more and more common. These
biological medicinal products
vary from recombinant proteins
to the very advanced cell therapy
products. The recently established
cell culture facility in NAM pro-
vides new possibilities for in vitro
determination of the biological
potency of such products. It also
facilitates pre-authorisation test-
ing and evaluation of the
methodology already during the
evaluation for marketing autho-
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Summary
Assistant researcher Yvonne Yli-
tolonen at work in the laboratory.
Enforcement and Inspection, Laboratory
National Agency for Medicines (NAM)
The official medicines control laboratory (OMCL) responsible for the independent quality control of
medicines in Finland is the Laboratory of National Agency for Medicines (NAM). The NAM-laboratory
is part of the European Official Medicines Control Laboratory (OMCL) -network, within which the 
laboratories co-operate in many fields of medicines testing and control.
In English
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Laboratory on alert
The medicinal products sold
through the legal distribution
chains in Finland can generally
be considered safe. Sometimes it
happens, however, that medicines
of unacceptable quality reach the
market. Therefore it is important
that NAM-laboratory is capable
to react rapidly to investigate
such suspected quality defects. A
good example of such a case oc-
curred in 2008: a cheap, harmful
substance had been added to he-
parin, thus causing the deaths of
numerous patients worldwide. In
order to ensure the safety of
Finnish patients, all batches of
heparin on the Finnish market on
that time were tested.
A growing problem is medi-
cines sold illegally via the Inter-
net. There is a great risk these
being counterfeit drugs. NAM-
laboratory collaborates with Cus-
toms Laboratory in order to ex-
tend the control to this type of il-
legal products. Another novel
and important field of collabora-
tion both nationally and Europe-
wide is the European OMCL-net-
work initiative to monitor the
quality of stockpiled medicines.
These activities are examples that
stress the importance of the work
done by the official control labo-
ratories, not only in assuring the
quality and safety of medicines
sold to patients via the legal dis-
tribution chain, but also in moni-
toring the health hazards of ille-
gal products and assuring the
quality of medicines to be used
only in a state of emergency.
Translation Jaana Vesterinen & Tom Wikberg
programme with the aim to test
the quality of Centrally Autho-
rized Products (CAP). 
In order to become full mem-
ber of the OMCL-network, a lab-
oratory has to be financially and
administratively independent, and
it has to have a formally recog-
nised quality management sys-
tem. The NAM-laboratory has
been a full member of the OM-
CL-network since it was estab-
lished. 
Quality assurance
As a guarantee for a high stan-
dard of performance, the NAM-
laboratory has implemented a
quality management system in ac-
cordance with standard ISO/IEC
17025 (General requirements for
the competence of testing and
calibration laboratories). Accord-
ing to this standard, all factors
affecting the quality of analysis
results must be controlled: the
personnel must have a high stan-
dard of knowledge and skills, the
work must be standardised and
described in standard operation
procedures. The laboratory of
NAM has regularly participated
in the external proficiency testing
studies and managed well. All the
most essential techniques have
been accredited by the Finnish
accreditation body (FINAS). Be-
cause of the special nature of
testing, the accreditation is based
on the so-called flexible scope.
This type of accreditation sets
special requirements for the man-
agement system and the compe-
tence of the personnel. In Fin-
land, the NAM-laboratory was
the very first one to achieve ac-
creditation based on flexible
scope.
rization, thus starting a new era
in the activities of the laboratory.
The microbiological purity of
parenteral products is extremely
important for the safety of pa-
tients. Not all authorities within
EU/EEA have microbiological
laboratories of their own. As an
example of the collaboration
with other European medicines
control laboratories NAM-labo-
ratory has performed microbio-
logical analyses for Latvia, Esto-
nia, Ireland and Sweden,. Devel-
opment of the advanced thera-
peutic products also sets novel
challenges for microbiological
testing.
OMCL-network 
The European OMCL laborato-
ries form a collaborative net-
work. Collectively they provide
the multidisciplinary array of
methods needed to reliably moni-
tor the quality of the several
thousand medicinal products
available on the European mar-
ket. Within this network, the lab-
oratories exchange samples and
data, thus minimizing the over-
lapping work between laborato-
ries and maximizing the number
of tested samples. The support
provided by this network is par-
ticularly important for small
member states like Finland.
The OMCL-network is coor-
dinated by the Department of Bi-
ological Standardisation, OMCL
Network and HealthCare (DBO),
which is a part of European Di-
rectorate for the Quality of Med-
icines & HealthCare (EDQM).
The network is for example uti-
lized by the European Medicines
Agency (EMEA) to carry through
the annual sampling and testing
